Navigation Links
Consumers Union Urges FDA To Require Safety Testing of Metal on Metal Hips and Other High Risk Implants
Date:4/18/2013

WASHINGTON, April 18, 2013 /PRNewswire-USNewswire/ -- Consumers Union urged the U.S. Food and Drug Administration today to adopt a proposed rule requiring metal hip implants to be reviewed through the agency's premarket approval (PMA) process to prove that the devices are safe and effective. 

In a comment letter to the FDA signed by more than 11,000 consumers, Consumers Union called on the agency to re-classify all high risk implantable medical devices under the PMA process so clinical evidence will be required to show their effectiveness and safety before the devices can be sold.

"Thousands of patients have been seriously injured by faulty metal on metal hip implants and other medical devices that were never properly tested before being cleared for sale," said Lisa McGiffert , Director of Consumers Union's Safe Patient Project (www.safePatientProject.org). "It's time to stop experimenting on patients and require more rigorous safety testing of all high risk implants to prevent flawed medical devices from reaching the market."

A copy of Consumers Union's letter to the FDA follows:

April 18, 2013
Food and Drug Administration
Docket No. FDA-2011-N-0661

To Whom It May Concern:

Consumers Union and the more than 11,000 people signing this letter due to their concern about high-risk implants are in full support of the FDA proposal (Docket No. FDA-2011-N-0661) to require all metal on metal (MoM) hips to be reviewed through the agency's premarket approval (PMA) process. It is too late for thousands of people who have been harmed by these implants that were cleared for market through a loophole in the law that allowed them to be sold without thorough review by the FDA to assure safety, even though they were classified as "high risk."

We also strongly support the proposal's requirement for makers of hip implants in this category that are already on the market to provide critical safety information to the agency within 90 days. However, it is troublesome that MoM hips can continue to be commercially distributed up to 90 days after the FDA order.

This order will finally require manufacturers to demonstrate clinical testing for safety and effectiveness before approval of new metal on metal hips. But at this time we are skeptical that any metal on metal hip implant could be safe for patients. Because of that, we urge the FDA to push all manufacturers of metal-on-metal hips to remove their products from the market, because of the high failure rates and high numbers of adverse events, especially experienced by women.

While the FDA has issued an alert about possible adverse events to the public, this does not guarantee that all affected patients have been given advice on monitoring their metal hips for problems. As was done in the UK, all patients with these implants should be notified about their risks and advised to get yearly tests for cobalt poisoning. Unless the FDA confirms that each manufacturer has done due diligence to notify every patient with these MoM hips, the problem has not been properly addressed.

The New York Times recently reported that a MoM hip sold by Johnson and Johnson had a 40% failure rate but the company continued to sell the remainder of their inventory, despite the knowledge of the failure rate. This kind of irresponsible behavior must stop. Requiring a more thorough review up front, as the current order proposes, will help to keep flawed devices from the market.

In addition, we strongly encourage the FDA to review and re-classify to PMA status all Class III implantable medical devices. Other high risk implanted medical devices like surgical mesh should also be put into the PMA approval track, requiring more clinical information. Patients suffering from harm due to surgical mesh implants have reported debilitating side effects from punctured organs to autoimmune disorders. Many have undergone multiple surgeries to remove the mesh, which has broken apart and traveled to other parts of the body.

Please move quickly to bring metal on metal hips and all other high risk implants under the PMA process so clinical evidence will be required to show their effectiveness and safety. 

Sincerely,

Lisa McGiffert
Consumers Union Safe Patient Project
506 West 14th Street Suite A
Austin TX 78701
lmcgiffert@consumer.org


'/>"/>
SOURCE Consumers Union
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthrageous Unveils Accountable Health The Missing Piece To Engage Consumers In Their Health And Achieve Accountable Care Goals
2. PCMA: New Report Shows Anti-PBM Laws Could Raise Health Care Costs for Oklahoma Businesses, Consumers, Government Programs
3. FastMed Urgent Care and MedVantx Offer Consumers First Ever Access to Free Samples of Medications through an Automated Medication Cabinet Across North Carolinas Largest Network of Urgent Care Centers
4. iPad Altering Interaction between Pharma Sales Forces, Physicians, & Consumers
5. MedVantx Achieves Significant Milestone of Providing Over $600 Million of Specialty Pharmacy Prescription Medications to Consumers
6. New Study Finds Use of Generic Prescription Drugs Saved Consumers and the U.S. Health Care System $1 Trillion over Past Decade
7. Consumers Choosing Organic Alternatives to Traditional Pharmaceuticals
8. NABP Applies for New .PHARMACY Generic Top-Level Domain to Provide a Secure Destination for Consumers
9. Consumers Are Advised to Be Aware of Hidden Costs in Some Discount Dental Plans
10. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
11. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
(Date:2/16/2017)...  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ) ... that executive management will participate in the RBC Capital ... 2017. Adrian Adams , Chief Executive Officer, will ... local time on Wednesday, February 22, 2017. ... may be accessed from the Investors section of the ...
(Date:2/16/2017)... Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... announced that Vincent J. Angotti has ... of the company,s board of directors, effective Monday, ... decades of experience leading executive and commercial teams ...
Breaking Medicine Technology:
(Date:2/19/2017)... CA (PRWEB) , ... February 19, 2017 , ... ProBrand Glitch is a set of ... With ProBrand Glitch users can easily reveal any logo with a glitch reveal in just ... users control over the style and animation of each preset. Use these presets to add ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a ... Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed ... roof. Smiles by Seese serves patients of all ages with excellence in general, restorative, ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... ... ... Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, ... , What are the critical reimbursement questions manufacturers should be asking before ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
Breaking Medicine News(10 mins):